Cut-off points for Polish-language versions of depression screening tools among patients with Type 2 diabetes

Kokoszka, Andrzej; Cichoń, Ewelina; Obrębski, Marcin; Kiejna, Andrzej; Rajba, Beata

doi:10.1016/j.pcd.2020.05.015

Cited by 8 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PHQ-9 questionnaire is a simple, reliable, and understandable tool for depression screening [15,16]. It was well validated for the Polish population thus it is highly recommended by the Polish Diabetes Association [14,15].…”

Section: Discussionmentioning

confidence: 99%

Depression in the elderly with type 2 diabetes mellitus

Rymkiewicz

Dzida

Myśliński

et al. 2022

Clinical Diabetology

View full text Add to dashboard Cite

the aim of this work was to explore the association of depression in elderly patients with type 2 diabetes (t2DM) with disease duration, microvascular complications and level of diabetes education. Methods Patients were divided into three main groups: group 1 aged 37-58 years, group 2 aged 70-79, group 3 aged ≥ 80 years. On the basis of collected medical records mean diabetes duration, microvascular complications, diabetes education level and depression severity were determined in particular age groups. results Microvascular complications occurred more frequently in older groups of patients with lower diabetes education level. In the oldest group moderately severe and severe depression was most frequent, while in the youngest group 50% of patients did not have any signs of depression, 43.4% presented mild depression, moderate and moderately severe depression was the least frequent (3.3%). Differences were statistically significant (p < 0.00001). Conclusions In patients with t2DM depression is more common in older age groups with longer average diabetes duration, lower diabetes education level and greater severity of microvascular disease complications. (clin Diabetol 2021; 10

show abstract

Section: Discussionmentioning

confidence: 99%

Depression in the elderly with type 2 diabetes mellitus

Rymkiewicz

Dzida

Myśliński

et al. 2022

Clinical Diabetology

View full text Add to dashboard Cite

show abstract

“…We used 19 points result as a cutoff point to determine OSA groups with poor and intensified symptoms of depression: the BDI (−) group (BDI ≤ 19) and BDI (+) group (BDI > 19), respectively. A validated BDI version in Polish was used in the study [ 44 , 45 ].…”

Section: Methodsmentioning

confidence: 99%

BDNF and proBDNF Serum Protein Levels in Obstructive Sleep Apnea Patients and Their Involvement in Insomnia and Depression Symptoms

Gabryelska

Turkiewicz

Ditmer

et al. 2022

JCM

View full text Add to dashboard Cite

Introduction: Obstructive sleep apnea (OSA) is a disorder that, apart from somatic sequelae, increases the risk of developing psychiatric conditions. Brain-derived neurotrophic factor (BDNF) signaling pathway is involved in the pathophysiology of depression and insomnia. Therefore, the study aimed to investigate differences in concentrations of BDNF and proBDNF in patients with OSA and healthy individuals, to evaluate diurnal changes of these proteins, and to assess the correlations with psychiatric symptoms. Methods: Sixty individuals following polysomnography (PSG) were divided into two groups based on the apnea-hypopnea index (AHI): OSA patients (AHI ≥ 30; n = 30) and control group (AHI < 5; n = 30). Participants filled out questionnaires: Beck Depression Inventory (BDI), Athens Insomnia Scale (AIS), and Pittsburgh Sleep Quality Index (PSQI). Peripheral blood was collected before and after PSG. Protein concentrations were measured using ELISA. OSA group was divided into subgroups: AIS (−)/AIS (+) (AIS > 5), PSQI (−)/PSQI (+) (PSQI > 5), and BDI (−)/BDI (+) (BDI > 19). Results: No differences in BDNF and proBDNF protein levels were observed between OSA and the control groups. However, BDNF and proBDNF evening protein concentrations were higher in the AIS (+) and PSQI (+) groups (p < 0.001 for all). The BDI (+) group was characterized by lower morning levels of both proteins (p = 0.047 and p = 0.003, respectively). Conclusions: BDNF signaling pathway might be involved in the pathophysiology of depression and insomnia in patients with OSA. BDNF and proBDNF protein levels might be useful in defining OSA phenotypes.

show abstract

“…The questionnaire does not define a lack of depression. A validated BDI version in Polish was used in the study (30,31).…”

Section: Beck Depression Inventory (Bdi)mentioning

confidence: 99%

Evaluation of daytime sleepiness and insomnia symptoms in OSA patients with a characterization of symptom-defined phenotypes and their involvement in depression comorbidity—a cross-sectional clinical study

Gabryelska,

Turkiewicz,

Białasiewicz

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

IntroductionRecent research highlights the significance of insomnia and sleepiness, shifting from obstructive sleep apnea (OSA) severity and sleep structure, in defining OSA phenotypes.ObjectivesThis study aimed to characterize insomnia and sleepiness associated with OSA phenotypes and assess their involvement in depression symptoms (DS) in OSA.Materials and methodsThis cross-sectional, clinical study included 181 participants who underwent polysomnography (PSG) and filled out questionnaires, including the Epworth Sleepiness Scale (ESS), Insomnia Severity Index (ISI), Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Index (BDI). They were categorized into phenotypes: insomnia–sleepiness (I + S; ESS ≥ 11; ISI ≥ 15; n = 20), sleepiness (S; ESS ≥ 11; ISI < 15; n = 22), insomnia (I; ESS < 11; ISI ≥ 15), and asymptomatic (A; ESS < 11; ISI<15; n=55).ResultsA linear regression model for the BDI score (R2 = 0.357, p < 0.001) included ISI score and subjective-to-objective sleep latency ratio. The ISI score was a predictive factor for mild and moderate DS [OR = 1.23 (95% CI: 1.09–1.38), p < 0.001 and OR = 1.39 (95% CI: 1.13–1.72), p = 0.002]. The I and I + S phenotypes are characterized by higher BDI scores (p < 0.001 and p = 0.02), longer subjective sleep latency (p = 0.008 and p = 0.04), and shorter subjective total sleep time (TST; p = 0.049 and p = 0.006) compared to A. Furthermore, the I and I + S groups had shorter subjective TST than S (p = 0.03 and p = 0.047). The I and I + S had higher BDI scores than A (p < 0.001 and p = 0.02, respectively) and S (p < 0.001 and p = 0.02, respectively). The I phenotype was associated with the risk of mild and moderate DS (OR = 5.61 (95% CI: 1.91–16.53), p < 0.001 and OR = 9.55 (95% CI: 1.81–50.48), p = 0.008 respectively). Moreover, the I + S phenotype presented an even greater risk for mild DS (OR = 10.29 (95% CI: 2.95–35.85), p < 0.001).ConclusionUsing clinical features for OSA phenotyping holds promise for finding OSA individuals with increased risk for DS occurrence.

show abstract

Cut-off points for Polish-language versions of depression screening tools among patients with Type 2 diabetes

Cited by 8 publications

References 43 publications

Depression in the elderly with type 2 diabetes mellitus

Depression in the elderly with type 2 diabetes mellitus

BDNF and proBDNF Serum Protein Levels in Obstructive Sleep Apnea Patients and Their Involvement in Insomnia and Depression Symptoms

Evaluation of daytime sleepiness and insomnia symptoms in OSA patients with a characterization of symptom-defined phenotypes and their involvement in depression comorbidity—a cross-sectional clinical study

Contact Info

Product

Resources

About